|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johansson SL and Cohen SM: Epidemiology
and etiology of bladder cancer. Semin Surg Oncol. 13:291–298. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Metts MC, Metts JC, Milito SJ and Thomas
CR Jr: Bladder cancer: A review of diagnosis and management. J Natl
Med Assoc. 92:285–294. 2000.PubMed/NCBI
|
|
5
|
Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Xu
X, Zhu Y, Li S and Zheng X: MicroRNA-409-3p inhibits migration and
invasion of bladder cancer cells via targeting c-Met. Mol Cells.
36:62–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Babjuk M, Burger M, Zigeuner R, Shariat
SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A,
Palou Redorta J, et al European Association of Urology: EAU
guidelines on non-muscle-invasive urothelial carcinoma of the
bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luke C, Tracey E, Stapleton A and Roder D:
Exploring contrary trends in bladder cancer incidence, mortality
and survival: Implications for research and cancer control. Intern
Med J. 40:357–362. 2010. View Article : Google Scholar
|
|
8
|
Zuiverloon TC, Nieuweboer AJ, Vékony H,
Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response
to bacillus Calmette-Guérin immunotherapy in high-risk bladder
cancer patients: A systematic review. Eur Urol. 61:128–145. 2012.
View Article : Google Scholar
|
|
9
|
Abdollah F, Gandaglia G, Thuret R,
Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF,
Perrotte P, et al: Incidence, survival and mortality rates of
stage-specific bladder cancer in United States: A trend analysis.
Cancer Epidemiol. 37:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meeks JJ, Bellmunt J, Bochner BH, Clarke
NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T,
et al: A systematic review of neoadjuvant and adjuvant chemotherapy
for muscle-invasive bladder cancer. Eur Urol. 62:523–533. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shariat SF, Karakiewicz PI, Palapattu GS,
Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A,
Sagalowsky A, et al: Nomograms provide improved accuracy for
predicting survival after radical cystectomy. Clin Cancer Res.
12:6663–6676. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Habuchi T, Marberger M, Droller MJ,
Hemstreet GP III, Grossman HB, Schalken JA, Schmitz-Dräger BJ,
Murphy WM, Bono AV, Goebell P, et al: Prognostic markers for
bladder cancer: International Consensus Panel on bladder tumor
markers. Urology. 66(Suppl 1): 64–74. 2005. View Article : Google Scholar
|
|
16
|
Bol MG, Baak JP, Buhr-Wildhagen S, Kruse
AJ, Kjellevold KH, Janssen EA, Mestad O and Øgreid P:
Reproducibility and prognostic variability of grade and lamina
propria invasion in stages Ta, T1 urothelial carcinoma of the
bladder. J Urol. 169:1291–1294. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo JC, Li J, Zhou L, Yang JY, Zhang ZG,
Liang ZY, Zhou WX, You L, Zhang TP and Zhao YP: CXCL12-CXCR7 axis
contributes to the invasive phenotype of pancreatic cancer.
Oncotarget. 7:62006–62018. 2016.PubMed/NCBI
|
|
18
|
Müller A, Homey B, Soto H, Ge N, Catron D,
Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al:
Involvement of chemokine receptors in breast cancer metastasis.
Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yasuoka H, Tsujimoto M, Yoshidome K,
Nakahara M, Kodama R, Sanke T and Nakamura Y: Cytoplasmic CXCR4
expression in breast cancer: Induction by nitric oxide and
correlation with lymph node metastasis and poor prognosis. BMC
Cancer. 8:3402008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu T, Wu Y, Helman JI, Wen Y, Wang C and
Li L: CXCR4 promotes oral squamous cell carcinoma migration and
invasion through inducing expression of MMP-9 and MMP-13 via the
ERK signaling pathway. Mol Cancer Res. 9:161–172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kato T, Fujita Y, Nakane K, Mizutani K,
Terazawa R, Ehara H, Kanimoto Y, Kojima T, Nozawa Y, Deguchi T, et
al: CCR1/CCL5 interaction promotes invasion of taxane-resistant PC3
prostate cancer cells by increasing secretion of MMPs 2/9 and by
activating ERK and Rac signaling. Cytokine. 64:251–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mashino K, Sadanaga N, Yamaguchi H, Tanaka
F, Ohta M, Shibuta K, Inoue H and Mori M: Expression of chemokine
receptor CCR7 is associated with lymph node metastasis of gastric
carcinoma. Cancer Res. 62:2937–2941. 2002.PubMed/NCBI
|
|
23
|
Comerford I, Harata-Lee Y, Bunting MD,
Gregor C, Kara EE and McColl SR: A myriad of functions and complex
regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive
immune system. Cytokine Growth Factor Rev. 24:269–283. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Förster R, Davalos-Misslitz AC and Rot A:
CCR7 and its ligands: Balancing immunity and tolerance. Nat Rev
Immunol. 8:362–371. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cabioglu N, Yazici MS, Arun B, Broglio KR,
Hortobagyi GN, Price JE and Sahin A: CCR7 and CXCR4 as novel
biomarkers predicting axillary lymph node metastasis in T1 breast
cancer. Clin Cancer Res. 11:5686–5693. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ishigami S, Natsugoe S, Nakajo A, Tokuda
K, Uenosono Y, Arigami T, Matsumoto M, Okumura H, Hokita S and
Aikou T: Prognostic value of CCR7 expression in gastric cancer.
Hepatogastroenterology. 54:1025–1028. 2007.PubMed/NCBI
|
|
27
|
Ma H, Gao L, Li S, Qin J, Chen L, Liu X,
Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced
epithelial-mesenchymal transition and is associated with lymph node
metastasis and poor overall survival in gastric cancer. Oncotarget.
6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Günther K, Leier J, Henning G, Dimmler A,
Weissbach R, Hohenberger W and Förster R: Prediction of lymph node
metastasis in colorectal carcinoma by expressionof chemokine
receptor CCR7. Int J Cancer. 116:726–733. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu S, Duan J, Zhou Z, Pang Q, Wuyang J,
Liu T, He X, Xinfa L and Chen Y: A critical role of CCR7 in
invasiveness and metastasis of SW620 colon cancer cell in vitro and
in vivo. Cancer Biol Ther. 7:1037–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Malietzis G, Lee GH, Bernardo D, Blakemore
AI, Knight SC, Moorghen M, Al-Hassi HO and Jenkins JT: The
prognostic significance and relationship with body composition of
CCR7-positive cells in colorectal cancer. J Surg Oncol. 112:86–92.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koizumi K, Kozawa Y, Ohashi Y, Nakamura
ES, Aozuka Y, Sakurai H, Ichiki K, Doki Y, Misaki T and Saiki I:
CCL21 promotes the migration and adhesion of highly lymph node
metastatic human non-small cell lung cancer Lu-99 in vitro. Oncol
Rep. 17:1511–1516. 2007.PubMed/NCBI
|
|
32
|
Takanami I: Overexpression of CCR7 mRNA in
nonsmall cell lung cancer: Correlation with lymph node metastasis.
Int J Cancer. 105:186–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kodama J, Hasengaowa, Kusumoto T, Seki N,
Matsuo T, Ojima Y, Nakamura K, Hongo A and Hiramatsu Y: Association
of CXCR4 and CCR7 chemokine receptor expression and lymph node
metastasis in human cervical cancer. Ann Oncol. 18:70–76. 2007.
View Article : Google Scholar
|
|
34
|
Wang J, Xi L, Hunt JL, Gooding W,
Whiteside TL, Chen Z, Godfrey TE and Ferris RL: Expression pattern
of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma
of the head and neck identifies a novel metastatic phenotype.
Cancer Res. 64:1861–1866. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yousefieh N, Hahto SM, Stephens AL and
Ciavarra RP: Regulated expression of CCL21 in the prostate tumor
microenvironment inhibits tumor growth and metastasis in an
orthotopic model of prostate cancer. Cancer Microenviron. 2:59–67.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heresi GA, Wang J, Taichman R, Chirinos
JA, Regalado JJ, Lichtstein DM and Rosenblatt JD: Expression of the
chemokine receptor CCR7 in prostate cancer presenting with
generalized lymphadenopathy: Report of a case, review of the
literature, and analysis of chemokine receptor expression. Urol
Oncol. 23:261–267. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mori T, Kim J, Yamano T, Takeuchi H, Huang
S, Umetani N, Koyanagi K and Hoon DS: Epigenetic up-regulation of
C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression
in melanoma cells. Cancer Res. 65:1800–1807. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishida K, Iwahashi M, Nakamori M, Nakamura
M, Yokoyama S, Iida T, Naka T, Nakamura Y and Yamaue H: High CCR7
mRNA expression of cancer cells is associated with lymph node
involvement in patients with esophageal squamous cell carcinoma.
Int J Oncol. 34:915–922. 2009.PubMed/NCBI
|
|
39
|
Ding Y, Shimada Y, Maeda M, Kawabe A,
Kaganoi J, Komoto I, Hashimoto Y, Miyake M, Hashida H and Imamura
M: Association of CC chemokine receptor 7 with lymph node
metastasis of esophageal squamous cell carcinoma. Clin Cancer Res.
9:3406–3412. 2003.PubMed/NCBI
|
|
40
|
Shi M, Chen D, Yang D and Liu XY:
CCL21-CCR7 promotes the lymph node metastasis of esophageal
squamous cell carcinoma by up-regulating MUC1. J Exp Clin Cancer
Res. 34:1492015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shang ZJ, Liu K and Shao Z: Expression of
chemokine receptor CCR7 is associated with cervical lymph node
metastasis of oral squamous cell carcinoma. Oral Oncol. 45:480–485.
2009. View Article : Google Scholar
|
|
42
|
Chen J, Cui YU, Liu L, Li C, Tang Y, Zhou
XU, Qi L and Zu X: CCR7 as a predictive biomarker associated with
computed tomography for the diagnosis of lymph node metastasis in
bladder carcinoma. Oncol Lett. 11:735–740. 2016.PubMed/NCBI
|
|
43
|
Elfiky AA and Rosenberg JE: Targeting
angiogenesis in bladder cancer. Curr Oncol Rep. 11:244–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vermeulen PB, Gasparini G, Fox SB, Toi M,
Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL,
et al: Quantification of angiogenesis in solid human tumours: An
international consensus on the methodology and criteria of
evaluation. Eur J Cancer. 32A:2474–2484. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vermeulen PB, Gasparini G, Fox SB,
Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, Van Marck E,
Magnani E, et al: Second international consensus on the methodology
and criteria of evaluation of angiogenesis quantification in solid
human tumours. Eur J Cancer. 38:1564–1579. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dickinson AJ, Fox SB, Persad RA, Hollyer
J, Sibley GN and Harris AL: Quantification of angiogenesis as an
independent predictor of prognosis in invasive bladder carcinomas.
Br J Urol. 74:762–766. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bochner BH, Cote RJ, Weidner N, Groshen S,
Chen SC, Skinner DG and Nichols PW: Angiogenesis in bladder cancer:
Relationship between microvessel density and tumor prognosis. J
Natl Cancer Inst. 87:1603–1612. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Goddard JC, Sutton CD, Furness PN, O'Byrne
KJ and Kockelbergh RC: Microvessel density at presentation predicts
subsequent muscle invasion in superficial bladder cancer. Clin
Cancer Res. 9:2583–2586. 2003.PubMed/NCBI
|
|
49
|
Canoğlu A, Göğüş C, Bedük Y, Orhan D,
Tulunay O and Baltaci S: Microvessel density as a prognostic marker
in bladder carcinoma: Correlation with tumor grade, stage and
prognosis. Int Urol Nephrol. 36:401–405. 2004. View Article : Google Scholar
|
|
50
|
Chaudhary R, Bromley M, Clarke NW, Betts
CD, Barnard RJ, Ryder WD and Kumar S: Prognostic relevance of
micro-vessel density in cancer of the urinary bladder. Anticancer
Res. 19:3479–3484. 1999.
|
|
51
|
Jaeger TM, Weidner N, Chew K, Moore DH,
Kerschmann RL, Waldman FM and Carroll PR: Tumor angiogenesis
correlates with lymph node metastases in invasive bladder cancer. J
Urol. 154:69–71. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shariat SF, Youssef RF, Gupta A, Chade DC,
Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R and
Lotan Y: Association of angiogenesis related markers with bladder
cancer outcomes and other molecular markers. J Urol. 183:1744–1750.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhou M, He L, Zu X, Zhang H, Zeng H and Qi
L: Lymphatic vessel density as a predictor of lymph node metastasis
and its relationship with prognosis in urothelial carcinoma of the
bladder. BJU Int. 107:1930–1935. 2011. View Article : Google Scholar
|
|
54
|
Jacquemier J, Mathoulin-Portier MP,
Valtola R, Charafe-Jauffret E, Geneix J, Houvenaeghel G, Puig B,
Bardou VJ, Hassoun J, Viens P, et al: Prognosis of breast-carcinoma
lymphagenesis evaluated by immunohistochemical investigation of
vascular-endothelial-growth-factor receptor 3. Int J Cancer.
89:69–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zeng Y, Opeskin K, Baldwin ME, Horvath LG,
Achen MG, Stacker SA, Sutherland RL and Williams ED: Expression of
vascular endothelial growth factor receptor-3 by lymphatic
endothelial cells is associated with lymph node metastasis in
prostate cancer. Clin Cancer Res. 10:5137–5144. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Longatto Filho A, Martins A, Costa SM and
Schmitt FC: VEGFR-3 expression in breast cancer tissue is not
restricted to lymphatic vessels. Pathol Res Pract. 201:93–99. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Valtola R, Salven P, Heikkilä P, Taipale
J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R and Alitalo
K: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis
in breast cancer. Am J Pathol. 154:1381–1390. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Partanen TA, Alitalo K and Miettinen M:
Lack of lymphatic vascular specificity of vascular endothelial
growth factor receptor 3 in 185 vascular tumors. Cancer.
86:2406–2412. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kahn HJ, Bailey D and Marks A: Monoclonal
antibody D2-40, a new marker of lymphatic endothelium, reacts with
Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol.
15:434–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Afonso J, Santos LL, Amaro T, Lobo F and
Longatto-Filho A: The aggressiveness of urothelial carcinoma
depends to a large extent on lymphovascular invasion - the
prognostic contribution of related molecular markers.
Histopathology. 55:514–524. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Braun M, Flucke U, Debald M,
Walgenbach-Bruenagel G, Walgenbach KJ, Höller T, Pölcher M,
Wolfgarten M, Sauerwald A, Keyver-Paik M, et al: Detection of
lymphovascular invasion in early breast cancer by D2-40
(podoplanin): A clinically useful predictor for axillary lymph node
metastases. Breast Cancer Res Treat. 112:503–511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Franchi A, Gallo O, Massi D, Baroni G and
Santucci M: Tumor lymphangiogenesis in head and neck squamous cell
carcinoma: A morphometric study with clinical correlations. Cancer.
101:973–978. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Beasley NJ, Prevo R, Banerji S, Leek RD,
Moore J, van Trappen P, Cox G, Harris AL and Jackson DG:
Intratumoral lymphangiogenesis and lymph node metastasis in head
and neck cancer. Cancer Res. 62:1315–1320. 2002.PubMed/NCBI
|
|
64
|
Maula SM, Luukkaa M, Grénman R, Jackson D,
Jalkanen S and Ristamäki R: Intratumoral lymphatics are essential
for the metastatic spread and prognosis in squamous cell carcinomas
of the head and neck region. Cancer Res. 63:1920–1926.
2003.PubMed/NCBI
|
|
65
|
Nakamura Y, Yasuoka H, Tsujimoto M, Imabun
S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K: Lymph
vessel density correlates with nodal status, VEGF-C expression, and
prognosis in breast cancer. Breast Cancer Res Treat. 91:125–132.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wang XL, Fang JP, Tang RY and Chen XM:
Different significance between intratumoral and peritumoral
lymphatic vessel density in gastric cancer: A retrospective study
of 123 cases. BMC Cancer. 10:2992010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Roma AA, Magi-Galluzzi C, Kral MA, Jin TT,
Klein EA and Zhou M: Peritumoral lymphatic invasion is associated
with regional lymph node metastases in prostate adenocarcinoma. Mod
Pathol. 19:392–398. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Dadras SS, Paul T, Bertoncini J, Brown LF,
Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC and Detmar
M: Tumor lymphangiogenesis: A novel prognostic indicator for
cutaneous melanoma metastasis and survival. Am J Pathol.
162:1951–1960. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dadras SS, Lange-Asschenfeldt B, Velasco
P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa
S, Mihm MC, et al: Tumor lymphangiogenesis predicts melanoma
metastasis to sentinel lymph nodes. Mod Pathol. 18:1232–1242. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Ma Y, Hou Y, Liu B, Li X, Yang S and Ma J:
Intratumoral lymphatics and lymphatic vessel invasion detected by
D2-40 are essential for lymph node metastasis in bladder
transitional cell carcinoma. Anat Rec (Hoboken). 293:1847–1854.
2010. View Article : Google Scholar
|
|
71
|
Fernández MI, Bolenz C, Trojan L, Steidler
A, Weiss C, Alken P, Grobholz R and Michel MS: Prognostic
implications of lymphangiogenesis in muscle-invasive transitional
cell carcinoma of the bladder. Eur Urol. 53:571–578. 2008.
View Article : Google Scholar
|
|
72
|
Miyata Y, Kanda S, Ohba K, Nomata K,
Hayashida Y, Eguchi J, Hayashi T and Kanetake H: Lymphangiogenesis
and angiogenesis in bladder cancer: prognostic implications and
regulation by vascular endothelial growth factors-A, -C, and -D.
Clin Cancer Res. 12:800–806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liang P, Hong JW, Ubukata H, Liu HR,
Watanabe Y, Katano M, Motohashi G, Kasuga T, Nakada I and Tabuchi
T: Increased density and diameter of lymphatic microvessels
correlate with lymph node metastasis in early stage invasive
colorectal carcinoma. Virchows Arch. 448:570–575. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Williams CS, Leek RD, Robson AM, Banerji
S, Prevo R, Harris AL and Jackson DG: Absence of lymphangiogenesis
and intratumoural lymph vessels in human metastatic breast cancer.
J Pathol. 200:195–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Birner P, Schindl M, Obermair A, Plank C,
Breitenecker G, Kowalski H and Oberhuber G: Lymphatic microvessel
density in epithelial ovarian cancer: Its impact on prognosis.
Anticancer Res. 20:2981–2985. 2000.PubMed/NCBI
|
|
76
|
Schoppmann SF, Birner P, Stöckl J, Kalt R,
Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K and Kerjaschki
D: Tumor-associated macrophages express lymphatic endothelial
growth factors and are related to peritumoral lymphangiogenesis. Am
J Pathol. 161:947–956. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tutunea-Fatan E, Majumder M, Xin X and
Lala PK: The role of CCL21/CCR7 chemokine axis in breast
cancer-induced lymphangiogenesis. Mol Cancer. 14:352015. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Redondo-Muñoz J, José Terol M,
García-Marco JA and García-Pardo A: Matrix metalloproteinase-9 is
up-regulated by CCL21/CCR7 interaction via extracellular
signal-regulated kinase-1/2 signaling and is involved in
CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and
migration. Blood. 111:383–386. 2008. View Article : Google Scholar
|
|
79
|
Li F, Zou Z, Suo N, Zhang Z, Wan F, Zhong
G, Qu Y, Ntaka KS and Tian H: CCL21/CCR7 axis activating chemotaxis
accompanied with epithelial-mesenchymal transition in human breast
carcinoma. Med Oncol. 31:1802014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xia X, Liu K, Zhang H and Shang Z:
Correlation between CCR7 expression and lymph node metastatic
potential of human tongue carcinoma. Oral Dis. 21:123–131. 2015.
View Article : Google Scholar
|
|
81
|
Yang J, Wang S, Zhao G and Sun B: Effect
of chemokine receptors CCR7 on disseminated behavior of human T
cell lymphoma: clinical and experimental study. J Exp Clin Cancer
Res. 30:512011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Calderaro J, Rebouissou S, de Koning L,
Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de
la Taille A, et al: PI3K/AKT pathway activation in bladder
carcinogenesis. Int J Cancer. 134:1776–1784. 2014. View Article : Google Scholar
|
|
83
|
Islam SS, Mokhtari RB, Akbari P, Hatina J,
Yeger H and Farhat WA: Simultaneous targeting of bladder tumor
growth, Survival, and epithelial-to-mesenchymal transition with a
novel therapeutic combination of acetazolamide (AZ) and
sulforaphane (SFN). Target Oncol. 11:209–227. 2016. View Article : Google Scholar
|
